Author

C. K. P. Mok

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:human· 5 Assay:proteomics· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 1 Organism:plant (other)· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

H. Lv· 6 shared N. C. Wu· 5 shared I. A. Wilson· 4 shared R. T. Y. So· 4 shared G. K. Yip· 3 shared M. Yuan· 3 shared R. Bruzzone· 3 shared W. Liang· 3 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

H. Lv

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Lack of neutralizing antibodies against the current circulating influenza viruses during the Omicron outbreak in Hong Kong

W. Liang, H. Lv, C. Chen, Y. Sun, D. S. Hui, C. K. P. Mok

The paper reports low neutralizing antibody levels against influenza A H1N1 and H3N2 viruses in adults during the Omicron outbreak, emphasizing the need for influenza vaccination.

bioRxiv · Feb 7, 2023 · PreprintImmunology

Egg-adaptation pathway of human influenza H3N2 virus is contingent on natural evolution

W. Liang, T. J. C. Tan, Y. Wang, H. Lv, Y. Sun, R. Bruzzone, C. K. P. Mok, N. C. Wu

The paper shows that natural mutations in human H3N2 HA influence the egg-adaptation pathway, affecting mutation emergence during vaccine production.

bioRxiv · Jan 31, 2022 · PreprintMicrobiology

XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants.

B. Vanhove, S. S. Marot, R. So, B. Gaborit, G. Evanno, I. Malet, G. Lafrogne, E. Mevel, C. Ciron, P.-J. Royer, E. Lheriteau, F. Raffi, R. Bruzzone, C. K. P. Mok, O. Duvaux, , V. Calvez

XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike RBD, neutralizes multiple variants by targeting multiple epitopes and shows potential in clinical trials.

bioRxiv · Apr 2, 2021Immunology

Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2

H. Lv, O. T.-Y. Tsang, R. T. Y. So, Y. Wang, H. Liu, G. K. Yip, Q. W. Teo, Y. Lin, W. Liang, J. Wang, W. W. Ng, I. A. Wilson, M. Peiris, N. C. Wu, C. K. P. Mok

The paper examines the serological response to the N-terminal domain (NTD) of SARS-CoV-2, showing it is less cross-reactive with SARS-CoV and less effective as an immunogen compared to the RBD.

bioRxiv · Feb 17, 2021 · PreprintImmunology

Evidence of antigenic imprinting in sequential Sarbecovirus immunization

H. Lv, R. T. Y. So, M. Yuan, H. Liu, C.-C. D. Lee, G. K. Yip, W. W. Ng, I. A. Wilson, J. S. M. Peiris, N. C. Wu, C. K. P. Mok

This study shows that prior exposure to one Sarbecovirus strain biases antibody response to a subsequent, antigenically distinct strain, suggesting antigenic imprinting affects immunity to SARS-CoV-2.

bioRxiv · Oct 14, 2020 · PreprintImmunology

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

B. Vanhove, O. Duvaux, J. Rousse, P.-J. Royer, G. Evanno, C. Ciron, E. Lheriteau, L. Vacher, N. Gervois, R. Oger, Y. Jacques, S. Conchon, A. Salama, R. Duchi, I. Lagutina, , J.-P. Soulillou

This paper describes the development of glyco-humanized swine polyclonal antibodies (GH-pAb) that neutralize SARS-CoV-2 with high potency and safety, and suggests clinical evaluation of the antibody XAV-19.

bioRxiv · Jul 25, 2020Immunology

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

H. Lv, N. C. Wu, O. T.-Y. Tsang, M. Yuan, R. A. P. M. Perera, W. S. Leung, R. T. Y. So, J. M. C. Chan, G. K. Yip, T. S. H. Chik, Y. Wang, C. Y. C. Choi, Y. Lin, W. W. Ng, J. Zhao, , C. K. P. Mok

This study examines cross-reactive antibody responses between SARS-CoV-2 and SARS-CoV, finding common binding but rare neutralization, suggesting non-neutralizing antibodies target conserved epitopes.

bioRxiv · Mar 15, 2020Microbiology

A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV

M. Yuan, N. C. Wu, X. Zhu, C.-C. D. Lee, R. T. Y. So, H. Lv, C. K. P. Mok, I. A. Wilson

Structural study of a cross-reactive SARS antibody reveals a conserved epitope on the SARS-CoV-2 receptor-binding domain.

bioRxiv · Mar 13, 2020Microbiology